Clinical OMICS

MAY-JUN 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/827649

Contents of this Issue

Navigation

Page 43 of 47

42 Clinical OMICs May/June 2017 www.clinicalomics.com Precision Medicine ple institutions to advance cancer care." Paradigm is currently working on reg- istry collaborations with large commu- nity oncology networks and academic health systems as it looks to tap existing infrastructure and clinical trial resources. Rennova Health Launches Advanced Precision Medicine Unit In early May, diagnostics and software company Rennova Health announced the formation of a precision medicine unit called Advanced Molecular Services Group, which combines the expertise of Rennova companies CollabRx, a provider of clinical decision support solutions; pharmacogenomics company Genomas; and Alethea Laboratories, Rennova's New Mexico laboratory. The focus of AMS Group will be on mental and behavioral health, oncology, urology and cardiovascular disease. Ser- vices to be offered by AMS will include interpretation of laboratory data of a patient's molecular profile to provide clinicians with guidance on appropriate treatment options. Rennova has licenced a mobile app intended to deliver this information to physicians with a beta launch scheduled for later this year. Scott Jenkins, Ph.D., a veteran health- care and life sciences executive, formerly with Applied Biosystems, IBM, Apple, and Dell Healthcare was named AMS Group CEO. "Precision medicine is exploding in part because of advances in diagnostic technologies and machine learning," said Dr. Jenkins. "Rennova has these key com- ponents to be a leader in this space," says Dr. Jenkins. "Every patient, physician and health organization needs immediate access to these life-changing tools, and we are going to deliver them." Human Longevity Launches Health Nucleus X Pilot Human Longevity, which focuses on a genomics-based approach to unlock- ing insights to human health launched Health Nucleus X (HNX) a pilot program designed to provide individual and their physicians actionable insights to proac- tively manage health using genomics and advance MRI. The pilot is being offered in the Health Nucleus facility in La Jolla, California from May 1 through June 30, 2017 for an intro- ductory price of $7,500. Patients wishing to participate will spend about three hours at Health Nucleus for core testing that includes whole genome sequencing and a whole body, 3T, non-contrast MRI. According to Cynthia Collins, CEO of Human Longevity HNX builds on the findings of Health Nucleus Platinum pro- gram, which is a full day of testing and also includes CT scans echocardiogram, EKG, and an expanded metabolic and lab testing regimen. "Our aim with the Health Nucleus and HNX is to give individuals and their phy- sicians the data to create integrated, per- sonalized and proactive health plans for their future," Collins said. HNX aims to bring the advantages of advanced testing to a broader popula- tion. HLI said it anticipates opening HNX facilities in additional cities after comple- tion of the pilot program. TGen, Critical Path Institute to Use Gates Foundation Award for Precision TB Treatments The Bill & Melinda Gates Foundation has awarded the Critical Path Institute (C-Path), a $1.1 million grant to enrich its Relational Sequencing TB Data Plat- form (ReSeqTB). Under a sub-award "The whole idea is to get discreet data into an EHR, so it can be used for clinical decision support," said Grant Wood, senior IT strategist at Intermountain Health- care. PDFs won't allow that. "The FHIR standards will allow us to store the information in EHRs and hope- fully mingle it with other clinical and family history data to allow physicians to use advanced decision support," he said. But the process isn't easy. "We have to take it in steps. It's quite advanced work," Wood said. Gil Alterovitz, M.D., principal investigator for Sync for Genes, said the project "is essentially the first step toward enabling clinical genomics through APIs. APIs are already commonly used in many consumer scenarios, such as Facebook and Uber, but it's a capability that the medical community hasn't had until recently. APIs are important for the practice of medicine because they "really enable you to have context and to be able to focus in on your patient and to ask specific ques- tions in a standard way." "There's this idea that when this data is available, it will empower patients, if they choose to share the data. It's about patient engagement. It's about enabling the ways we share this information," Dr. Alterovitz said. "Once we have that infrastructure available, there's so much we can do. What we learn in one setting can be used in other settings." (continued from previous page) (continued from previous page) (continued on next page) nevarpp / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2017